Success Metrics

Active Trials

4(100%)

Phase Distribution

Ph phase_2

100%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 2Efficacy & side effects

4(100.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(4)

Detailed Status

Recruiting4

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

N/A

Most Advanced

Phase 2

Trials by Phase

Phase 24 (100.0%)

Trials by Status

recruiting4100%

Recent Activity

4 active trials

Showing 4 of 4

recruitingphase_2

A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma

NCT06624644

recruitingphase_2

Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma

NCT06831136

recruitingphase_2

Optimizing Neoadjuvant Treatment Regimens for Locally Advanced Esophageal Squamous Cell Carcinoma

NCT06907602

recruitingphase_2

Immunotherapy and Carbon Ion Radiotherapy In Solid Cancers With Stable Disease

NCT05229614

Clinical Trials (4)

Showing 4 of 4 trials

NCT06624644Phase 2

A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma

Recruiting

NCT06831136Phase 2

Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma

Recruiting

NCT06907602Phase 2

Optimizing Neoadjuvant Treatment Regimens for Locally Advanced Esophageal Squamous Cell Carcinoma

Recruiting

NCT05229614Phase 2

Immunotherapy and Carbon Ion Radiotherapy In Solid Cancers With Stable Disease

Recruiting

All 4 trials loaded

Drug Details

Intervention Type: BIOLOGICAL
Total Trials: 4